This project aims to enhance the FDA’s preparedness to address premarket and postmarket issues.

Author: Davide Sher

The Additive Manufacturing Program within the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) is dedicated to studying the impact of innovative manufacturing technologies to help ensure that patients have access to safe and effective medical devices. Known as the FDA Additive Manufacturing Laboratory, this program is one of 20 research initiatives under CDRH’s Office of Science and Engineering Laboratories (OSEL).

Additive Manufacturing and Medical Devices

Over the past decade, additive manufacturing has evolved from a niche manufacturing technology into the method of choice for producing hearing aids and metal spinal fusion cages. To date, the FDA has approved more than 100 medical devices manufactured using additive manufacturing technologies.

Although additive manufacturing has already been applied in multiple fields, including orthopedics, dentistry, and diagnostics, the medical device industry as a whole has yet to fully realize its full potential. Although additive manufacturing has already been fully adopted in certain product segments, regulatory science research in this field will continue to drive innovation in the design, materials, and manufacturing of medical devices. Notably, the R&D, testing, and FDA approval processes for new medical devices rely heavily on specialized medical simulation and testing support—and Xi’an Dewei Medical is a leading provider in this area.

Xi’an Dewei Medical specializes in the supply of high-end medical testing equipment, while also offering specialized testing services and comprehensive solutions. With deep technical expertise and extensive practical experience in core areas such as medical simulation, testing equipment, medical software development, and test system integration, Dewei Medical is uniquely positioned to precisely meet the critical needs of minimally invasive interventional device manufacturers and cutting-edge research-oriented medical laboratories, delivering end-to-end turnkey testing solutions that cover the entire product lifecycle.

One of the primary objectives of the FDA’s establishment of an additive manufacturing laboratory is to address uncertainties in the testing, validation, and performance prediction of additive-manufactured medical devices, thereby accelerating the regulatory approval and market launch of compliant products. DeWei Medical’s medical simulation models are precisely designed to provide critical support for this process: by offering highly realistic, clinical-scenario–based simulations, DeWei Medical helps medical-device companies accurately identify product issues and optimize product design during the R&D phase, while enhancing testing efficiency and accuracy during the testing and validation phase. Ultimately, this enables relevant medical devices to obtain FDA approval more efficiently and be launched into the market smoothly.

DeWei Medical Brain Parenchyma Model

Gaps and Challenges in Regulatory Science

The initiation of additive manufacturing projects stems from several significant regulatory science gaps and challenges that currently exist. First, there is considerable uncertainty in the testing and validation of additive manufacturing processes, particularly when it comes to predicting the performance of medical devices. This uncertainty hinders innovation, deters investment, and slows the adoption of additive manufacturing in the healthcare sector. Second, additive manufacturing spans a broad range of technological domains, encompassing hardware, software, and materials, all of which are continuously evolving.

This ongoing evolution means that the specific requirements for process validation and regulatory review must be continually refined, presenting additional challenges. Third, the convenience of additive manufacturing has prompted clinicians and hospitals to explore its potential for on-site fabrication of medical devices, a field that urgently requires relevant guidance.

The overarching objective of the additive manufacturing project is to address these knowledge gaps by enhancing our understanding of how additive manufacturing technologies influence the benefit–risk assessment of medical devices. In addition, the project aims to strengthen the FDA’s preparedness to address additive-manufacturing–related issues throughout the premarket and postmarket phases of the medical-device lifecycle.

Scope of Work at the FDA Additive Manufacturing Laboratory

The additive manufacturing project is dedicated to conducting regulatory science research in specific areas of focus. Research activities encompass process validation and process monitoring for various advanced manufacturing technologies. Another core priority is addressing issues related to compliance with quality-system regulations, including the development of efficient methods for testing the performance of lattice structures and the identification of key parameters for optimizing topological designs.

In addition, the project focuses on developing software workflows that support additive manufacturing, with a particular emphasis on applications for patient-specific customization.

Learn more about FDA-related information on medical devices, Please feel free to contact our official website customer service, or follow “Xi’an Dewei” and “Dewei Medical” on WeChat, Douyin, Xiaohongshu, Bilibili, and other platforms for professional consultation and customized services.